Solid Biosciences Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Solid Biosciences Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Steadiness Ratio: Sales and profit both fell in each of the last 3 years. Less steady than 96% of Healthcare companies in United States.
Cash quality
Profit Cash Ratio
—Data incomplete
Self-Funding Ratio
-105.5×Over the last 3 years operating cash was negative while the company kept spending on investment (capex).
Lower than 82% of Healthcare companies in United States.
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
0/3 · 0/3Sales and profit both fell in each of the last 3 years.
Less steady than 96% of Healthcare companies in United States.
Growth Efficiency Ratio
—Sales fell 100%
Sales fell 100% in 3 years, so extra profit per extra sales cannot be measured.
Asset Productivity Ratio
-100% / -11%In 3 years sales changed by -100% while total assets changed by -11%. Assets grew faster than sales.
Balance-sheet strength
Debt Due Cover Ratio
-74.3×Operating cash was negative last year, while some debt falls due within a year.
Lower than 79% of Healthcare companies in United States.
Cash Cushion Ratio
+25%Cash, after subtracting all debt, equals 25% of its market value (net cash).
Higher than 66% of Healthcare companies in United States.
Tangible Assets Ratio
—Data incomplete
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (10)
Solid Biosciences Inc. made a loss over the last year. Solid Biosciences Inc. owes $0.11 for every $1 it owns. Solid Biosciences Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossSolid Biosciences Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
1.77The share price is 1.77 times Solid Biosciences Inc.'s book value per share, lower than 63% of Healthcare companies in United States.
Market cap
$664 MThe total market value of all of Solid Biosciences Inc.'s shares at today's price (share price × number of shares), larger than 59% of Healthcare companies in United States. PosiCap size class: Mini Cap.
Net worth (book value)
$374 MWhat Solid Biosciences Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$3.49Net worth divided by the number of shares. The share price of $6.19 is 1.8 times this, which is the P/B above.
Return on equity (ROE)
-65.5%Solid Biosciences Inc. lost 65.5% of its shareholders' money over the last year, lower than 59% of Healthcare companies in United States.
Owes vs Owns
0.11×Solid Biosciences Inc. owes $0.11 for every $1 it owns (low), lower than 85% of Healthcare companies in United States.
Dividend yield
NoneSolid Biosciences Inc. does not currently pay a dividend.
Profit growth
LossSolid Biosciences Inc. made a loss in each of the last two years.
Cash vs debt
Net cashSolid Biosciences Inc. held $167 M more cash than debt (net cash) at Dec 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Solid Biosciences Inc.: $664 M ÷ $374 M (30 Jun 2026) = 1.8.
What is Solid Biosciences Inc.'s return on equity?
Solid Biosciences Inc. lost 65.5% of its shareholders' money over the last year, lower than 59% of Healthcare companies in United States.
How much does Solid Biosciences Inc. owe compared with what it owns?
Solid Biosciences Inc. owes $0.11 for every $1 it owns (low), lower than 85% of Healthcare companies in United States.
Does Solid Biosciences Inc. pay a dividend?
No. Solid Biosciences Inc. does not currently pay a dividend.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.